特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

癌治療用遺伝子医学の世界市場 - 市場シェア、市場規模、動向、業界分析、および将来予測

Genomics in Cancer Care Market Share, Size, Trends, & Industry Analysis Report, By Product type; By Technology, By Application; By End Use; and By Region: Segment Forecast, 2019 - 2025

発行 Polaris Market Research 商品コード 817637
出版日 ページ情報 英文 113 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
癌治療用遺伝子医学の世界市場 - 市場シェア、市場規模、動向、業界分析、および将来予測 Genomics in Cancer Care Market Share, Size, Trends, & Industry Analysis Report, By Product type; By Technology, By Application; By End Use; and By Region: Segment Forecast, 2019 - 2025
出版日: 2019年03月01日 ページ情報: 英文 113 Pages
概要

当レポートでは、癌治療用遺伝子医学の世界市場を取り上げ、その市場規模、成長促進要因と阻害要因、市場機会、業界動向、また市場競争状況など幅広い調査を基に市場の現状分析ならびに将来予測を行っています。さらに市場を製品タイプ別、技術タイプ別、用途別、エンドユーザ別、および地域別に分類した詳細な分析と予測を提供しています。

第1章 市場概要および範囲

  • 調査目的および調査範囲
  • 調査上の想定条件
  • 調査手法
  • 本調査の成果
  • 利害関係者

第2章 エグゼクティブ・サマリー

  • 市場の定義
  • 市場分類

第3章 癌治療用遺伝子医学市場見通し

  • 癌治療用遺伝子医学 - 業界概観
    • 主要企業
    • 注目企業
  • 癌治療用遺伝子医学 - エコシステム分析
    • 疾患概要
    • 商業的現況
  • 癌治療用遺伝子医学市場ダイナミクス
    • 癌治療用遺伝子医学 - 市場影響要因
  • 業界分析 - Porterのファイブフォース
  • 癌治療用遺伝子医学市場PEST分析
  • 癌治療用遺伝子医学市場バリューチェーン分析
  • 癌治療用遺伝子医学業界動向
  • 競争力ランキング分析

第4章 癌治療用遺伝子医学市場の製品タイプ別市場規模および将来予測

  • 重要な調査結果
  • 消耗品
  • 器具類
  • サービス

第5章 癌治療用遺伝子医学市場の技術タイプ別市場規模および将来予測

  • 重要な調査結果
  • ゲノム解読
  • PCR (ポリメラーゼ連鎖反応)
  • マイクロアレイ核酸抽出および精製

第6章 癌治療用遺伝子医学市場の用途別市場規模および将来予測

  • 診断
  • オーダメイド医療
  • 薬剤送達
  • 研究

第7章 癌治療用遺伝子医学市場のエンドユーザ別市場規模および将来予測

  • 病院
  • 研究所
  • 学術研究機関

第8章 癌治療用遺伝子医学市場の地域別市場規模および将来予測

  • 重要な調査結果
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ベルギー
    • ロシア
    • オランダ
    • 他の欧州諸国
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • シンガポール
    • マレーシア
    • インドネシア
    • タイ
    • フィリピン
    • 他のアジア太平洋諸国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • 他のラテンアメリカ諸国
  • 中東およびアフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • 他の中東・アフリカ諸国

第9章 企業プロファイル

  • Aligent Technologies
  • Roche Diagnostics
  • Beckman Coulter
  • Illumina, Inc.
  • Affymetric
  • Cancer Genetic Inc.
  • Bio-rad Labs
  • Pacific Bio-Sciences
  • Sigma Aldrich Corporation
  • GE Healthcare
  • Quest Diagnostics
  • Abbott Laboratories
  • PerkinElmer
  • Luminex
目次
Product Code: PM1607

The global genomics in cancer care market size is anticipated to reach USD 14.6 billion by 2025 growing at a CAGR of 17.7% from 2019 to 2025 according to a new report published by Polaris Market Research. The report 'Genomics in Cancer Care Market Share, Size, Trends, & Industry Analysis Report, By Product type (Consumables, Instruments, Services); By Technology, By Application; By End Use; and By Region: Segment Forecast, 2019 - 2025' provides insights on the current market scenario and the future prospects.

In 2018, by product type, instrument segment captures the largest market shares in terms of revenue and hold major share in the market. Regionally, North America accounted for the major share in the global market.

The market is primarily driven by increasing prevalence of cancer patients globally, and rising demand for diagnostic coupled with the availability of cost effective and technologically advanced technology. Additionally, awareness and growing preference for personalized medicines is also influencing the market growth. Moreover, continuous investment on research and developments by the biotechnology & pharmaceutical companies would also fuel the market growth.

Product segment is further sub-segmented into consumables and reagents, instruments, and services. Instruments market holds the major share in the market owning to the rapid technological advancements, and continuous efforts by the manufacturers for providing digitalization in the instruments for its easy use. While consumables and reagents hold second largest position for market followed by the service sub segment.

Based on technology, the market is segmented as genome sequencing, PCR, microarray nucleic acid extraction and purification. Genome sequencing holds the major market share in 2017, and would continue to experience growth during the forecast period. The growth in this segment is majorly driven by the effective and precise diagnosis results, and rising awareness for its use in cancer diagnosis. Moreover, advantages like growing demand for cost-effective technologies, and flexibility in this technique would also influence the growth of genome sequencing market.

On the basis of application, the market is further segmented as diagnostics, personalized medicines, drug discovery, and Research. This application is majorly used for diagnosis of cancer. Diagnostics holds the largest market share which is majorly attributed to the growing number of cancer patients worldwide.

Research institute is the largest segment as an end user for the market, and would hold dominating position during the forecast period. The growth of genomics market in cancer care is primarily driven by the need for accurate screening techniques that gives to the point diagnosis of cancer.

Geographically, North America holds a dominating position in the global genomics in cancer care market followed by Europe and Asia Pacific. The market growth in North America is driven by the presence of refined research & development infrastructure for the researchers, large pool of patients suffering from cancer, and high healthcare expenditure by the individuals. Whereas, Asia Pacific is expected to reach remarkable growth owning to the increased penetration rate of these technologies and improving research and development expenditure by the biopharma industries.

The leading companies operating in this industry include Agilent Technologies, Roche Diagnostics, Beckman Coulter, Illumina, Inc., Affymetrix, Cancer Genetic Inc., Bio-Rad Labs, Pacific Bio-science, Sigma Aldrich Corporation, GE Healthcare, Quest Diagnostics, Abbott Laboratories, PerkinElmer, and Luminex.

Key Findings from the study suggest technology available in the market are continuously concentrating on the technological advancements that will reduce the efforts and provide with accurate diagnosis of cancer. The leading companies while developing new technologies considers the factors such as increasing awareness for the use of this technology, and reaching the untapped market. North America is presumed to dominate the global market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China.

Polaris Market Research has segmented the genomics in cancer care market on the basis of product type, technology, application, end user and region:

Genomics in Cancer Care Product Type Outlook (Revenue, USD Million, 2015 - 2025)

Consumables

Instruments

Service

Genomics in Cancer Care Technology Type Outlook (Revenue, USD Million, 2015 - 2025)

Gene Sequencing

PCR

Microarray Nucleic Acid Extraction and Purification

Genomics in Cancer Care Application Outlook (Revenue, USD Million, 2015 - 2025)

Diagnostics

Personalized Medicines

Drug Delivery

Research

Genomics in Cancer Care Product End Use Outlook (Revenue, USD Million, 2015 - 2025)

Hospitals

Research Institutes

Academic Research

Genomics in Cancer Care Product Regional Outlook (Revenue, USD Million, 2015 - 2025)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Belgium

Russia

Netherlands

Rest of Europe

Asia-Pacific

China

India

Japan

Korea

Singapore

Malaysia

Indonesia

Thailand

Philippines

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East & Africa

UAE

Saudi Arabia

South Africa

Rest of MEA

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-away
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market definition
  • 2.2. Market segmentation

3. Genomics in Cancer Care Market Insights

  • 3.1. Genomics in Cancer Care - Industry snapshot
    • 3.1.1. Leading Companies
    • 3.1.2. Key Companies to Watch
  • 3.2. Genomics in Cancer Care - Ecosystem analysis
    • 3.2.1. Disease overview
    • 3.2.2. Commercial Landscape
  • 3.3. Genomics in Cancer Care Market Dynamics
    • 3.3.1. Genomics in Cancer Care - Market Forces
      • 3.3.1.1. Genomics in Cancer Care Market Driver Analysis
      • 3.3.1.2. Genomics in Cancer Care Market Restraint/Challenges analysis
      • 3.3.1.3. Genomics in Cancer Care Market Opportunity Analysis
  • 3.4. Industry analysis - Porter's five forces
    • 3.4.1. Bargaining power of supplier
    • 3.4.2. Bargaining power of buyer
    • 3.4.3. Threat of substitute
    • 3.4.4. Threat of new entrant
    • 3.4.5. Degree of competition
  • 3.5. Genomics in Cancer Care Market PEST Analysis
  • 3.6. Genomics in Cancer Care Market Value Chain Analysis
  • 3.7. Genomics in Cancer Care Industry Trends
  • 3.8. Competitive Ranking Analysis, 2018

4. Genomics in Cancer Care Market Size and Forecast, by Product Types

  • 4.1. Key Findings
  • 4.2. Consumables
  • 4.3. Instruments
  • 4.4. Service

5. Genomics in Cancer Care Market Size and Forecast, by Technology Type

  • 5.1. Key Findings
  • 5.2. Genome Sequencing
  • 5.3. PCR
  • 5.4. Microarray Nucleic Acid Extraction & Purification

6. Genomics in Cancer Care Market Size and Forecast, by Application

  • 6.1. Diagnostics
  • 6.2. Personalized Medicines
  • 6.3. Drug Delivery
  • 6.4. Research

7. Genomics in Cancer Care Market Size and Forecast, by End Use

  • 7.1. Hospitals
  • 7.2. Research Institutes
  • 7.3. Academic Research Institutes

8. Genomics in Cancer Care Market Size and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. UK
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Belgium
    • 8.3.7. Russia
    • 8.3.8. Netherlands
    • 8.3.9. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. Korea
    • 8.4.5. Singapore
    • 8.4.6. Malaysia
    • 8.4.7. Indonesia
    • 8.4.8. Thailand
    • 8.4.9. Philippines
    • 8.4.10. Rest of Asia-Pacific
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Argentina
    • 8.5.4. Rest of LATAM
  • 8.6. Middle East & Africa
    • 8.6.1. UAE
    • 8.6.2. Saudi Arabia
    • 8.6.3. South Africa
    • 8.6.4. Rest of MEA

9. Company Profiles

  • 9.1. Aligent Technologies
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Developments
  • 9.2. Roche Diagnostics
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Developments
  • 9.3. Beckman Coulter
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Developments
  • 9.4. Illumina, Inc.
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Developments
  • 9.5. Affymetric
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Developments
  • 9.6. Cancer Genetic Inc.
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Developments
  • 9.7. Bio-rad Labs
    • 9.7.1. Overview
    • 9.7.2. Financials
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Developments
  • 9.8. Pacific Bio-Sciences
    • 9.8.1. Overview
    • 9.8.2. Financials
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Developments
  • 9.9. Sigma Aldrich Corporation
    • 9.9.1. Overview
    • 9.9.2. Financials
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Developments
  • 9.10. GE Healthcare
    • 9.10.1. Overview
    • 9.10.2. Financials
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Developments
  • 9.11. Quest Diagnostics
    • 9.11.1. Overview
    • 9.11.2. Financials
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Developments
  • 9.12. Abbott Laboratories
    • 9.12.1. Overview
    • 9.12.2. Financials
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Developments
  • 9.13. PerkinElmer
    • 9.13.1. Overview
    • 9.13.2. Financials
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Developments
  • 9.14. Luminex
    • 9.14.1. Overview
    • 9.14.2. Financials
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Developments